The following is a listing of myeloma treatments associated with this tag.
View all treatments in development for myeloma patients around the US.
Mezagitamab
Mezagitamab (TAK-079) is a monoclonal antibody that targets and attaches to the CD38 protein that may be found on multiple myeloma cells.
Nivolumab
Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.
SEA-BCMA
SEA-BCMA is a monoclonal antibody that targets the B-Cell Maturation Antigen (BCMA) and is made with Sugar Engineered Antibody (SEA) technology. Researchers believe this approach may improve immune response to cancer cells.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of treatments in development for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.
The following is a listing of treatments in development for patients with multiple myeloma who have received one to two prior lines of therapy.
Mezagitamab
Mezagitamab (TAK-079) is a monoclonal antibody that targets and attaches to the CD38 protein that may be found on multiple myeloma cells.
Nivolumab
Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of treatments in development for patients with multiple myeloma who have received three or more prior lines of therapy.
Mezagitamab
Mezagitamab (TAK-079) is a monoclonal antibody that targets and attaches to the CD38 protein that may be found on multiple myeloma cells.
Nivolumab
Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.
SEA-BCMA
SEA-BCMA is a monoclonal antibody that targets the B-Cell Maturation Antigen (BCMA) and is made with Sugar Engineered Antibody (SEA) technology. Researchers believe this approach may improve immune response to cancer cells.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of treatments in development for patients with Smoldering Myeloma.
Nivolumab
Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.
SparkCures Verified Accurate, up-to-date information. Learn more
The following is a listing of treatments in development for patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).
The following is a listing of myeloma clinical trials associated with this tag.
View all active clinical trials around the US.
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
DARATUMUMAB COMBINATION THERAPY
SparkCures Verified Accurate, up-to-date information. Learn more
A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma
CD38-TARGETED IMMUNOPETA Multi-Center, Phase 3, Randomized Trial of Matched Unrelated Donor (MUD) Versus HLA-Haploidentical Relate...
MISMATCHED RELATED VS. MATCHED UNRELATED DONORA Phase 1a/b Study to Evaluate the Safety & Tolerability of JSP191 in Combination With a Regimen of Low Dos...
JSP191 CONDITIONING REGIMENA Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a ...
TRIPLET INDUCTION + 1 OR 2-DRUG MAINTENANCEA Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study of AK117/Placebo in Combination W...
AK117/PLACEBO WITH AZACITIDINEA Randomized, Multi-Center, Phase II Study of Vemurafenib Plus Obinutuzumab Vs. Cladribine Plus Rituximab i...
VEMURAFENIB AND OBINUTUZUMABAlpha/Beta TCD HCT in Patients With Inherited BMF Disorders
T CELL RECEPTOR DEPLETION IN STEM CELL TRANSPLANTAn Attenuated Schedule Dara-RVd Induction for Patients With Newly Diagnosed Multiple Myeloma Who Are Eligib...
DARATUMUMAB COMBINATION INDUCTIONCardioprotection With Dexrazoxane in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS)...
HEART PROTECTION W/DEXRAZOXANE DURING CHEMOTHERAPYElotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
ELOTUZUMAB + IBERDOMIDE POST ABECMAIsatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
ISATUXIMAB DURING STEM CELL TRANSPLANTIsatuximab Plus Lenalidomide and Dexamethasone for Frail and/or Much Older Patients With Newly Diagnosed Mu...
ISATUXIMAB IN FRAIL PATIENTSNivolumab As An Adjunctive Therapy In Relapsed Refractory Multiple Myeloma Patients With Sub-Optimal Respon...
NIVOLUMAB POST TREATMENT WITH IDE-CELOpen-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic He...
ISATUXIMAB AFTER ALLOGENEIC STEM CELL TRANSPLANTPhase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agen...
ISATUXIMAB IN COMBINATION WITH NOVEL AGENTSPhase 1b Study of Pembrolizumab, Decitabine +/- Venetoclax Combination Therapy in Patients With Relapsed or...
PEMBROLIZUMAB, DECITABINE +/- VENETOCLAXPhase I Clinical Trial of Bcl2 Inhibitor Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven...
VENETOCLAX PLUS LENALIDOMIDEPhase II Randomized Trial of Population PK Dosed Melphalan With Interleukin-6 Blockade With Siltuximab Vesr...
MELPHALAN WITH OR WITHOUT SILTUXIMABPilot Study of Daratumumab in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-CyBorD...
DARATUMUMAB FOR PATIENTS WITH RENAL FAILUREPost-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients
POST-TRANSPLANT MAINTENANCE THERAPYSafety and Efficacy of Elotuzumab, CC-92480, and Dexamethasone in Relapsed/Refractory Myeloma After CD38- a...
ELOTUZUMAB COMBINATION THERAPYStudy of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly Newly Diagnosed ...
SUBQ DARATUMUMAB IN ELDERLY PATIENTS²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor...
²¹¹AT-OKT10-B10 WITH FLUDARABINEThe following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.
SparkCures Verified Accurate, up-to-date information. Learn more
A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma
CD38-TARGETED IMMUNOPETA Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a ...
TRIPLET INDUCTION + 1 OR 2-DRUG MAINTENANCEAn Attenuated Schedule Dara-RVd Induction for Patients With Newly Diagnosed Multiple Myeloma Who Are Eligib...
DARATUMUMAB COMBINATION INDUCTIONIsatuximab Plus Lenalidomide and Dexamethasone for Frail and/or Much Older Patients With Newly Diagnosed Mu...
ISATUXIMAB IN FRAIL PATIENTSPhase I Clinical Trial of Bcl2 Inhibitor Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven...
VENETOCLAX PLUS LENALIDOMIDEPhase II Randomized Trial of Population PK Dosed Melphalan With Interleukin-6 Blockade With Siltuximab Vesr...
MELPHALAN WITH OR WITHOUT SILTUXIMABStudy of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly Newly Diagnosed ...
SUBQ DARATUMUMAB IN ELDERLY PATIENTS²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor...
²¹¹AT-OKT10-B10 WITH FLUDARABINEThe following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
DARATUMUMAB COMBINATION THERAPYSparkCures Verified Accurate, up-to-date information. Learn more
A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma
CD38-TARGETED IMMUNOPETIsatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
ISATUXIMAB DURING STEM CELL TRANSPLANTNivolumab As An Adjunctive Therapy In Relapsed Refractory Multiple Myeloma Patients With Sub-Optimal Respon...
NIVOLUMAB POST TREATMENT WITH IDE-CELOpen-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic He...
ISATUXIMAB AFTER ALLOGENEIC STEM CELL TRANSPLANTPhase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agen...
ISATUXIMAB IN COMBINATION WITH NOVEL AGENTSPhase I Clinical Trial of Bcl2 Inhibitor Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven...
VENETOCLAX PLUS LENALIDOMIDEPhase II Randomized Trial of Population PK Dosed Melphalan With Interleukin-6 Blockade With Siltuximab Vesr...
MELPHALAN WITH OR WITHOUT SILTUXIMABSafety and Efficacy of Elotuzumab, CC-92480, and Dexamethasone in Relapsed/Refractory Myeloma After CD38- a...
ELOTUZUMAB COMBINATION THERAPY²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor...
²¹¹AT-OKT10-B10 WITH FLUDARABINEThe following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
DARATUMUMAB COMBINATION THERAPYSparkCures Verified Accurate, up-to-date information. Learn more
A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma
CD38-TARGETED IMMUNOPETElotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
ELOTUZUMAB + IBERDOMIDE POST ABECMANivolumab As An Adjunctive Therapy In Relapsed Refractory Multiple Myeloma Patients With Sub-Optimal Respon...
NIVOLUMAB POST TREATMENT WITH IDE-CELOpen-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic He...
ISATUXIMAB AFTER ALLOGENEIC STEM CELL TRANSPLANTPhase 1-2 UMBRELLA Trial Evaluating Isatuximab With or Without Dexamethasone in Combination With Novel Agen...
ISATUXIMAB IN COMBINATION WITH NOVEL AGENTSPhase I Clinical Trial of Bcl2 Inhibitor Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven...
VENETOCLAX PLUS LENALIDOMIDESafety and Efficacy of Elotuzumab, CC-92480, and Dexamethasone in Relapsed/Refractory Myeloma After CD38- a...
ELOTUZUMAB COMBINATION THERAPY²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor...
²¹¹AT-OKT10-B10 WITH FLUDARABINEThe following is a listing of clinical trials for patients with Smoldering Myeloma.
The following is a listing of clinical trials for patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).
The following is a listing of myeloma tags that are associated with this tag.
B-Cell Maturation Antigen (BCMA)
B-Cell Maturation Antigen (BCMA) is a protein that may be found on the surface of myeloma cells. BCMA may be used as a target to help treatments find and destroy myeloma cells.
CD38
CD38 is a protein that may be found on the surface of many immune system cells (including multiple myeloma cells). This protein may be used as a way for treatments to target (or find) myeloma cells.
Programmed Death Receptor-1 (PD-1)
PD-1 is a protein found on the surface of immune cells (called T cells). This protein acts as an "off switch" that may stop your immune system from attacking cancer cells.